Denice Tsao‐Wei
About
Denice Tsao‐Wei is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Denice Tsao‐Wei has authored 116 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 45 papers in Molecular Biology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Denice Tsao‐Wei's work include Prostate Cancer Treatment and Research (13 papers), Neuroblastoma Research and Treatments (12 papers) and Cancer Treatment and Pharmacology (12 papers). Denice Tsao‐Wei is often cited by papers focused on Prostate Cancer Treatment and Research (13 papers), Neuroblastoma Research and Treatments (12 papers) and Cancer Treatment and Pharmacology (12 papers). Denice Tsao‐Wei collaborates with scholars based in United States, Germany and Canada. Denice Tsao‐Wei's co-authors include Susan Groshen, Marc C. Chamberlain, Dennis Salonga, Kathleen D. Danenberg, Ralf Metzger, Jan Stoehlmacher, Heinz‐Josef Lenz, Cynthia G. Leichman, Martin R. Johnson and Heinz-Josef Lenz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.
In The Last Decade
Denice Tsao‐Wei
110 papers receiving 4.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Denice Tsao‐Wei United States | 33 | 2.1k | 1.9k | 919 | 865 | 716 | 116 | 4.7k | ||
| Maurizio Martini Italy | 44 | 1.9k 0.9× | 2.3k 1.3× | 1.1k 1.2× | 1.0k 1.2× | 1.3k 1.8× | 281 | 6.5k | ||
| Christian Dittrich Austria | 33 | 1.6k 0.8× | 1.4k 0.8× | 833 0.9× | 594 0.7× | 664 0.9× | 136 | 4.0k | ||
| D L Trump United States | 33 | 2.0k 1.0× | 1.1k 0.6× | 1.6k 1.8× | 1.1k 1.3× | 411 0.6× | 76 | 4.8k | ||
| Federica Tomao Italy | 38 | 2.0k 1.0× | 1.2k 0.6× | 1.0k 1.1× | 949 1.1× | 731 1.0× | 243 | 4.9k | ||
| Antonio Jimeno United States | 39 | 3.5k 1.7× | 3.5k 1.9× | 1.4k 1.5× | 583 0.7× | 1.3k 1.8× | 169 | 7.2k | ||
| Juanita Lopez United Kingdom | 28 | 2.6k 1.3× | 1.9k 1.0× | 1.3k 1.4× | 404 0.5× | 821 1.1× | 144 | 4.9k | ||
| Ignacio Garrido‐Laguna United States | 32 | 3.1k 1.5× | 1.8k 1.0× | 1.1k 1.2× | 483 0.6× | 1.5k 2.1× | 160 | 4.9k | ||
| Cinzia Orlandini Italy | 29 | 2.2k 1.1× | 622 0.3× | 877 1.0× | 748 0.9× | 630 0.9× | 74 | 3.7k | ||
| Roger von Moos Switzerland | 41 | 4.2k 2.0× | 1.4k 0.7× | 1.9k 2.0× | 1.1k 1.3× | 668 0.9× | 234 | 6.2k | ||
| Nilofer S. Azad United States | 41 | 3.8k 1.9× | 2.3k 1.2× | 1.4k 1.5× | 1.1k 1.3× | 1.3k 1.7× | 205 | 6.3k |
Countries citing papers authored by Denice Tsao‐Wei
Since
Specialization
Citations
This map shows the geographic impact of Denice Tsao‐Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denice Tsao‐Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denice Tsao‐Wei more than expected).
Fields of papers citing papers by Denice Tsao‐Wei
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Denice Tsao‐Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denice Tsao‐Wei. The network helps show where Denice Tsao‐Wei may publish in the future.
Co-authorship network of co-authors of Denice Tsao‐Wei
This figure shows the co-authorship network connecting the top 25 collaborators of Denice Tsao‐Wei. A scholar is included among the top collaborators of Denice Tsao‐Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denice Tsao‐Wei. Denice Tsao‐Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gitlitz, Barbara J., Vinay Duddalwar, Kevin G. King, et al.. (2024). Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. Oncotarget. 15(1). 444–458.
2.
Sadeghi, Sarmad, Nataliya Mar, Denice Tsao‐Wei, et al.. (2024). Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4577–4577.
3.
Nawrocki, Steffan T., Kaijin Wu, Denice Tsao‐Wei, et al.. (2023). Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial. Clinical Cancer Research. 29(24). 5087–5103.
4.
Tuscano, Joseph M., Emanual Maverakis, Susan Groshen, et al.. (2019). A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clinical Cancer Research. 25(23). 7004–7013.
5.
Pinto, Navin, Steven G. DuBois, Araz Marachelian, et al.. (2018). Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood & Cancer. 65(7). e27023–e27023.
6.
Mohrbacher, Ann, Allen S. Yang, Susan Groshen, et al.. (2017). Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clinical Cancer Research. 23(16). 4550–4555.
7.
Yu, Steven, Stephen V. Liu, Andrew V. Schally, et al.. (2017). A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 15(6). 742–749.
8.
Dorff, Tanya B., Susan Groshen, Agustin A. García, et al.. (2016). Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 16(1). 360–360.
9.
Liu, Stephen V., Denice Tsao‐Wei, Shigang Xiong, et al.. (2014). Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clinical Cancer Research. 20(24). 6277–6283.
10.
Dorff, Tanya B., Denice Tsao‐Wei, Susan Groshen, et al.. (2013). Efficacy of Oxaliplatin Plus Pemetrexed in Chemotherapy Pretreated Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 11(4). 416–422.
11.
Gitlitz, Barbara J., Denice Tsao‐Wei, Susan Groshen, et al.. (2011). A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial. Journal of Thoracic Oncology. 7(3). 574–578.
12.
Iqbal, Syma, Denice Tsao‐Wei, David I. Quinn, et al.. (2010). Phase I Clinical Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Patients With Advanced Solid Tumors. American Journal of Clinical Oncology. 34(1). 27–31.
13.
Cheung, Eric, Jacek Pinski, Tanya B. Dorff, et al.. (2009). Oral Fenretinide in Biochemically Recurrent Prostate Cancer: A California Cancer Consortium Phase II Trial. Clinical Genitourinary Cancer. 7(1). 43–50.
14.
Dorff, Tanya B., Denice Tsao‐Wei, Gus Miranda, et al.. (2008). Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World Journal of Urology. 27(1). 39–44.
15.
Saha, Baisakhi, Benjaporn Chaiwun, Denice Tsao‐Wei, et al.. (2007). Telomerase and Markers of Cellular Proliferation Are Associated With the Progression of Cervical Intraepithelial Neoplasia Lesions. International Journal of Gynecological Pathology. 26(3). 214–222.
16.
Schneider‐Burrus, Sylke, Yuusuke Uchida, Jan Brabender, et al.. (2005). Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. Journal of the American College of Surgeons. 200(3). 336–344.
17.
Formenti, Silvia C., Darcy Spicer, Kristin A. Skinner, et al.. (2002). Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. International Journal of Radiation Oncology*Biology*Physics. 52(2). 397–405.
18.
Lord, Reginald V., Peter I. Tsai, Kathleen D. Danenberg, et al.. (2001). Retinoic acid receptor-α messenger RNA expression is increased and retinoic acid receptor-γ expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence. Surgery. 129(3). 267–276.
19.
Park, Jae‐Hyun, Jan Stoehlmacher, Wu Zhang, et al.. (2001). Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. International Journal of Colorectal Disease. 17(1). 46–49.
20.
Zhou, Qing, et al.. (2000). Contortrostatin, a dimeric disintegrin from contortrix contortrix, inhibits breast cancer progression. Breast Cancer Research and Treatment. 61(3). 249–259.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maurizio Martini Breakdown of academic impact, for papers by Christian Dittrich Breakdown of academic impact, for papers by D L Trump Breakdown of academic impact, for papers by Federica Tomao Breakdown of academic impact, for papers by Antonio Jimeno Breakdown of academic impact, for papers by Juanita Lopez Breakdown of academic impact, for papers by Ignacio Garrido‐Laguna Breakdown of academic impact, for papers by Cinzia Orlandini Breakdown of academic impact, for papers by Roger von Moos Breakdown of academic impact, for papers by Nilofer S. Azad